Prescient advances new therapies for hard-to-treat cancers
Clinical stage biotech Prescient Therapeutics is developing new therapies for cancers of unmet need, aggressive...
Clinical stage biotech Prescient Therapeutics is developing new therapies for cancers of unmet need, aggressive...
The first patient has been dosed in Prescient Therapeutics Phase 2a clinical trial of PTX-100...
Cell and gene therapy is changing the game when it comes to cancer treatment and...
CAR-T therapy is leading the race as the holy grail to cure cancer but like...
Prescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatment and...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.